The cyclins: a family of widely expressed tumor antigens?

References

• Sadovnikova E, Jopling LA, Soo KS, Stauss HJ. Generation of human tumor-reactive cytotoxic T cells against peptides presented by non-self HLA class I molecules. Eur. J. Immunol.28(1), 193–200 (1998).
   PubMed Web of Science ®Google Scholar
• Hunter T, Pines J. Cyclins and cancer. Cell66(6), 1071–1074 (1991).
   PubMed Web of Science ®Google Scholar
• Zhou P, Jiang W, Zhang YJ et al. Antisense to cyclin D1 inhibits growth and reverses the transformed phenotype of human esophageal cancer cells. Oncogene11(3), 571–580 (1995).
   PubMed Web of Science ®Google Scholar
• Li K, Lin SY, Brunicardi FC, Seu P. Use of RNA interference to target cyclin E-overexpressing hepatocellular carcinoma. Cancer Res.63(13), 3593–3597 (2003).
   PubMed Web of Science ®Google Scholar
• De Falco M, De Luca A. Cell cycle as a target of antineoplastic drugs. Curr. Pharm. Des.16(12), 1417–1426 (2010).
   PubMed Web of Science ®Google Scholar
• Wang RF, Wang X, Atwood AC, Topalian SL, Rosenberg SA. Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen. Science284(5418), 1351–1354 (1999).
   PubMed Web of Science ®Google Scholar
• Wolfel T, Hauer M, Schneider J et al. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science269(5228), 1281–1284 (1995).
   PubMed Web of Science ®Google Scholar
• Kao H, Marto JA, Hoffmann TK et al. Identification of Cyclin B1 as a shared human epithelial tumor-associated antigen recognized by T cells. J. Exp. Med.194(9), 1313–1324 (2001).
   PubMed Web of Science ®Google Scholar
• Dahl AM, Beverley PC, Stauss HJ. A synthetic peptide derived from the tumor-associated protein mdm2 can stimulate autoreactive, high avidity cytotoxic T lymphocytes that recognize naturally processed protein. J. Immunol.157(1), 239–246 (1996).
   PubMed Web of Science ®Google Scholar
• Kolb HJ, Mittermuller J, Clemm C et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood76(12), 2462–2465 (1990).
   PubMed Web of Science ®Google Scholar
• Small EJ, Schellhammer PF, Higano CS et al. Placebo-controlled Phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J. Clin. Oncol.24(19), 3089–3094 (2006).
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Dudley ME. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr. Opin. Immunol.21(2), 233–240 (2009).
   PubMed Web of Science ®Google Scholar
• Cheever MA, Allison JP, Ferris AS et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin. Cancer Res.15(17), 5323–5337 (2009).
   PubMed Web of Science ®Google Scholar
• Oka Y, Sugiyama H. WT1 peptide vaccine, one of the most promising cancer vaccines: its present status and the future prospects. Immunotherapy2(5), 591–594 (2010).
   PubMed Web of Science ®Google Scholar
• Gao L, Yang TH, Tourdot S, Sadovnikova E, Hasserjian R, Stauss HJ. Allo-major histocompatibility complex-restricted cytotoxic T lymphocytes engraft in bone marrow transplant recipients without causing graft-versus-host disease. Blood94(9), 2999–3006 (1999).
   PubMed Web of Science ®Google Scholar
• Kondo E, Maecker B, Weihrauch M et al. Cyclin D1-specific cytotoxic T lymphocytes are present in the repertoire of cancer patients: implications for cancer immunotherapy. Clin. Cancer Res.14(20), 6574–6579 (2008).
   PubMed Web of Science ®Google Scholar
• Wang M, Sun L, Qian J et al. Cyclin D1 as a universally expressed mantle cell lymphoma-associated tumor antigen for immunotherapy. Leukemia23(7), 1320–1328 (2009).
   PubMed Web of Science ®Google Scholar
• Volm M, Koomagi R, Mattern J, Stammler G. Cyclin A is associated with an unfavourable outcome in patients with non-small-cell lung carcinomas. Br. J. Cancer75(12), 1774–1778 (1997).
   PubMed Web of Science ®Google Scholar
• Kuhling H, Alm P, Olsson H et al. Expression of cyclins E, A, and B, and prognosis in lymph node-negative breast cancer. J. Pathol.199(4), 424–431 (2003).
   PubMed Web of Science ®Google Scholar
• Ohashi R, Gao C, Miyazaki M et al. Enhanced expression of cyclin E and cyclin A in human hepatocellular carcinomas. Anticancer Res.21(1B), 657–662 (2001).
   PubMed Web of Science ®Google Scholar
• Renshaw AA, Loughlin KR, Dutta A. Cyclin A and MIB1 (Ki67) as markers of proliferative activity in primary renal neoplasms. Mod. Pathol.11(10), 963–966 (1998).
   PubMed Web of Science ®Google Scholar
• Michalides R, van Tinteren H, Balkenende A et al. Cyclin A is a prognostic indicator in early stage breast cancer with and without tamoxifen treatment. Br. J. Cancer86(3), 402–408 (2002).
   PubMed Web of Science ®Google Scholar
• Dobashi Y, Shoji M, Jiang SX, Kobayashi M, Kawakubo Y, Kameya T. Active cyclin A-CDK2 complex, a possible critical factor for cell proliferation in human primary lung carcinomas. Am. J. Pathol.153(3), 963–972 (1998).
   PubMed Web of Science ®Google Scholar
• Handa K, Yamakawa M, Takeda H, Kimura S, Takahashi T. Expression of cell cycle markers in colorectal carcinoma: superiority of cyclin A as an indicator of poor prognosis. Int. J. Cancer84(3), 225–233 (1999).
   PubMed Web of Science ®Google Scholar
• Kondo E, Maecker B, Draube A et al. The shared tumor associated antigen cyclin-A2 is recognized by high-avidity T-cells. Int. J. Cancer125(10), 2474–2478 (2009).
   PubMed Web of Science ®Google Scholar
• Yang R, Nakamaki T, Lübbert M et al. Cyclin A1 expression in leukemia and normal hematopoietic cells. Blood93(6), 2067–2074 (1999).
   PubMed Web of Science ®Google Scholar
• Holm C, Ora I, Brunhoff C, Anagnostaki L, Landberg G, Persson JL. Cyclin A1 expression and associations with disease characteristics in childhood acute lymphoblastic leukemia. Leuk. Res.30(3), 254–261 (2006).
   PubMed Web of Science ®Google Scholar
• Muller-Tidow C, Diederichs S, Schrader MG et al. Cyclin A1 is highly expressed in aggressive testicular germ cell tumors. Cancer Lett.190(1), 89–95 (2003).
   PubMed Web of Science ®Google Scholar
• Kondo E, Gryschok L, Schultze JL, von Bergwelt-Baildon MS. Using CD40-activated B cells to efficiently identify epitopes of tumor antigens. J. Immunother.32(2), 157–160 (2009).
   PubMed Web of Science ®Google Scholar
• Hassan KA, El-Naggar AK, Soria JC, Liu D, Hong WK, Mao L. Clinical significance of cyclin B1 protein expression in squamous cell carcinoma of the tongue. Clin. Cancer Res.7(8), 2458–2462 (2001).
   PubMed Web of Science ®Google Scholar
• Wang A, Yoshimi N, Ino N, Tanaka T, Mori H. Overexpression of cyclin B1 in human colorectal cancers. J. Cancer Res. Clin. Oncol.123(2), 124–127 (1997).
   PubMed Web of Science ®Google Scholar
• Soria JC, Jang SJ, Khuri FR et al. Overexpression of cyclin B1 in early-stage non-small cell lung cancer and its clinical implication. Cancer Res.60(15), 4000–4004 (2000).
   PubMed Web of Science ®Google Scholar
• El-Ghobashy AA, Shaaban AM, Herod J, Innes J, Prime W, Herrington CS. Overexpression of cyclins A and B as markers of neoplastic glandular lesions of the cervix. Gynecol. Oncol.92(2), 628–634 (2004).
   PubMed Web of Science ®Google Scholar
• Nozoe T, Korenaga D, Kabashima A, Ohga T, Saeki H, Sugimachi K. Significance of cyclin B1 expression as an independent prognostic indicator of patients with squamous cell carcinoma of the esophagus. Clin. Cancer Res.8(3), 817–822 (2002).
   PubMed Web of Science ®Google Scholar
• Song Y, Zhao C, Dong L et al. Overexpression of cyclin B1 in human esophageal squamous cell carcinoma cells induces tumor cell invasive growth and metastasis. Carcinogenesis29(2), 307–315 (2008).
   PubMed Web of Science ®Google Scholar
• Takeno S, Noguchi T, Kikuchi R, Uchida Y, Yokoyama S, Muller W. Prognostic value of cyclin B1 in patients with esophageal squamous cell carcinoma. Cancer94(11), 2874–2881 (2002).
   PubMed Web of Science ®Google Scholar
• Dong Y, Sui L, Watanabe Y, Sugimoto K, Tokuda M. Clinical relevance of cyclin B1 overexpression in laryngeal squamous cell carcinoma. Cancer Lett.177(1), 13–19 (2002).
   PubMed Web of Science ®Google Scholar
• Covini G, Chan EK, Nishioka M, Morshed SA, Reed SI, Tan EM. Immune response to cyclin B1 in hepatocellular carcinoma. Hepatology25(1), 75–80 (1997).
   PubMed Web of Science ®Google Scholar
• Suzuki H, Graziano DF, McKolanis J, Finn OJ. T cell-dependent antibody responses against aberrantly expressed cyclin B1 protein in patients with cancer and premalignant disease. Clin. Cancer Res.11(4), 1521–1526 (2005).
   PubMed Web of Science ®Google Scholar
• Koziol JA, Zhang JY, Casiano CA et al. Recursive partitioning as an approach to selection of immune markers for tumor diagnosis. Clin. Cancer Res.9(14), 5120–5126 (2003).
   PubMed Web of Science ®Google Scholar
• Sorensen RB, Andersen RS, Svane IM et al. CD8 T-cell responses against cyclin B1 in breast cancer patients with tumors overexpressing p53. Clin. Cancer Res.15(5), 1543–1549 (2009).
   PubMed Web of Science ®Google Scholar
• Vella LA, Yu M, Fuhrmann SR, El-Amine M, Epperson DE, Finn OJ. Healthy individuals have T-cell and antibody responses to the tumor antigen cyclin B1 that when elicited in mice protect from cancer. Proc. Natl Acad. Sci. USA106(33), 14010–14015 (2009).
   PubMed Web of Science ®Google Scholar
• von Bergwelt-Baildon MS. Biological and biotechnological analysis of CD40-activated B cells and antigen presenting cells. von Ossietzky C (Ed.). Universität Oldenburg, Germany (2003).
   Google Scholar
• Andersen RS, Sorensen RB, Ritter C et al. Identification of a cyclin B1-derived CTL epitope eliciting spontaneous responses in both cancer patients and healthy donors. Cancer Immunol. Immunother.60(2), 227–234 (2010).
   PubMed Web of Science ®Google Scholar
• Park SH, Yu GR, Kim WH, Moon WS, Kim JH, Kim DG. NF-Y-dependent cyclin B2 expression in colorectal adenocarcinoma. Clin. Cancer Res.13(3), 858–867 (2007).
   PubMed Web of Science ®Google Scholar
• Hofmann HS, Hansen G, Burdach S, Bartling B, Silber RE, Simm A. Discrimination of human lung neoplasm from normal lung by two target genes. Am. J. Respir. Crit. Care Med.170(5), 516–519 (2004).
   PubMed Web of Science ®Google Scholar
• Hernandez J, Lee PP, Davis MM, Sherman LA. The use of HLA A2.1/p53 peptide tetramers to visualize the impact of self tolerance on the TCR repertoire. J. Immunol.164(2), 596–602 (2000).
   PubMed Web of Science ®Google Scholar
• Muller H, Lukas J, Schneider A et al. Cyclin D1 expression is regulated by the retinoblastoma protein. Proc. Natl Acad. Sci. USA91(8), 2945–2949 (1994).
   PubMed Web of Science ®Google Scholar
• Ratschiller D, Heighway J, Gugger M et al. Cyclin D1 overexpression in bronchial epithelia of patients with lung cancer is associated with smoking and predicts survival. J. Clin. Oncol.21(11), 2085–2093 (2003).
   PubMed Web of Science ®Google Scholar
• Arber N, Hibshoosh H, Moss SF et al. Increased expression of cyclin D1 is an early event in multistage colorectal carcinogenesis. Gastroenterology110(3), 669–674 (1996).
   PubMed Web of Science ®Google Scholar
• Arber N, Gammon MD, Hibshoosh H et al. Overexpression of cyclin D1 occurs in both squamous carcinomas and adenocarcinomas of the esophagus and in adenocarcinomas of the stomach. Hum. Pathol.30(9), 1087–1092 (1999).
   PubMed Web of Science ®Google Scholar
• Weinschenk T, Gouttefangeas C, Schirle M et al. Integrated functional genomics approach for the design of patient-individual antitumor vaccines. Cancer Res.62(20), 5818–5827 (2002).
   PubMed Web of Science ®Google Scholar
• Dengjel J, Decker P, Schoor O et al. Identification of a naturally processed cyclin D1 T-helper epitope by a novel combination of HLA class II targeting and differential mass spectrometry. Eur. J. Immunol.34(12), 3644–3651 (2004).
   PubMed Web of Science ®Google Scholar
• Barnes DM, Gillett CE. Cyclin D1 in breast cancer. Breast Cancer Res. Treat.52(1–3), 1–15 (1998).
   PubMed Web of Science ®Google Scholar
• Al-Aynati MM, Radulovich N, Ho J, Tsao MS. Overexpression of G1-S cyclins and cyclin-dependent kinases during multistage human pancreatic duct cell carcinogenesis. Clin. Cancer Res.10(19), 6598–6605 (2004).
   PubMed Web of Science ®Google Scholar
• Nakamura S, Yatabe Y, Seto M. Cyclin D1 overexpression in malignant lymphomas. Pathol. Int.47(7), 421–429 (1997).
   PubMed Web of Science ®Google Scholar
• Han EK, Lim JT, Arber N, Rubin MA, Xing WQ, Weinstein IB. Cyclin D1 expression in human prostate carcinoma cell lines and primary tumors. Prostate35(2), 95–101 (1998).
   PubMed Web of Science ®Google Scholar
• Dao T, Korontsvit T, Zakhaleva V, Haro K, Packin J, Scheinberg DA. Identification of a human cyclin D1-derived peptide that induces human cytotoxic CD4 T cells. PLoS ONE4(8), e6730 (2009).
   PubMed Web of Science ®Google Scholar
• Shi FD, Zhang JY, Liu D et al. Preferential humoral immune response in prostate cancer to cellular proteins p90 and p62 in a panel of tumor-associated antigens. Prostate63(3), 252–258 (2005).
   PubMed Web of Science ®Google Scholar
• Takano Y, Kato Y, Masuda M, Ohshima Y, Okayasu I. Cyclin D2, but not cyclin D1, overexpression closely correlates with gastric cancer progression and prognosis. J. Pathol.189(2), 194–200 (1999).
   PubMed Web of Science ®Google Scholar
• Faussillon M, Monnier L, Junien C, Jeanpierre C. Frequent overexpression of cyclin D2/cyclin-dependent kinase 4 in Wilms’ tumor. Cancer Lett.221(1), 67–75 (2005).
   PubMed Web of Science ®Google Scholar
• Watson DS, Brotherick I, Shenton BK et al. Cyclin D3 expression, cell proliferation and pathological stage of human primary colorectal cancer. Oncology,56(1), 66–72 (1999).
   PubMed Web of Science ®Google Scholar
• Hedberg Y, Roos G, Ljungberg B, Landberg G. Cyclin D3 protein content in human renal cell carcinoma in relation to cyclin D1 and clinico–pathological parameters. Acta. Oncol.41(2), 175–181 (2002).
   PubMed Web of Science ®Google Scholar
• Li H, Lahti JM, Valentine M et al. Molecular cloning and chromosomal localization of the human cyclin C (CCNC) and cyclin E (CCNE) genes: deletion of the CCNC gene in human tumors. Genomics32(2), 253–259 (1996).
   PubMed Web of Science ®Google Scholar
• Ohata N, Ito S, Yoshida A et al. Highly frequent allelic loss of chromosome 6q16–23 in osteosarcoma: involvement of cyclin C in osteosarcoma. Int. J. Mol. Med.18(6), 1153–1158 (2006).
   PubMed Web of Science ®Google Scholar
• Galamb O, Sipos F, Molnar B, Szoke D, Spisak S, Tulassay Z. Evaluation of malignant and benign gastric biopsy specimens by mRNA expression profile and multivariate statistical methods. Cytometry B Clin. Cytom.72(5), 299–309 (2007).
   PubMed Web of Science ®Google Scholar
• Husdal A, Bukholm G, Bukholm IR. The prognostic value and overexpression of cyclin A is correlated with gene amplification of both cyclin A and cyclin E in breast cancer patient. Cell. Oncol.28(3), 107–116 (2006).
   PubMed Web of Science ®Google Scholar
• Bondi J, Husdal A, Bukholm G, Nesland JM, Bakka A, Bukholm IR. Expression and gene amplification of primary (A, B1, D1, D3, and E) and secondary (C and H) cyclins in colon adenocarcinomas and correlation with patient outcome. J. Clin. Pathol.58(5), 509–514 (2005).
   PubMed Web of Science ®Google Scholar
• Yasmeen A, Berdel WE, Serve H, Müller-Tidow C. E- and A-type cyclins as markers for cancer diagnosis and prognosis. Expert Rev. Mol. Diagn.3(5), 617–633 (2003).
   PubMed Web of Science ®Google Scholar
• Guo X, Wu Y, Hartley RS. Cold-inducible RNA-binding protein contributes to human antigen R and cyclin E1 deregulation in breast cancer. Mol. Carcinog.49(2), 130–140 (2010).
   PubMed Web of Science ®Google Scholar
• Finn OJ. Immunological weapons acquired early in life win battles with cancer late in life. J. Immunol.181(3), 1589–1592 (2008).
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat. Med.10(9), 909–915 (2004).
   PubMed Web of Science ®Google Scholar
• Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature449(7161), 419–426 (2007).
   PubMed Web of Science ®Google Scholar
• Nagorsen D, Thiel E. Clinical and immunologic responses to active specific cancer vaccines in human colorectal cancer. Clin. Cancer Res.12(10), 3064–3069 (2006).
   PubMed Web of Science ®Google Scholar
• Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu. Rev. Immunol.21, 685–711 (2003).
   PubMed Web of Science ®Google Scholar
• Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat. Rev. Immunol.6(4), 295–307 (2006).
   PubMed Web of Science ®Google Scholar
• Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat. Rev. Immunol.4(12), 941–952 (2004).
   PubMed Web of Science ®Google Scholar
• Chang MH, You SL, Chen CJ et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J. Natl Cancer Inst.101(19), 1348–1355 (2009).
   PubMed Web of Science ®Google Scholar
• Kahn JA. HPV vaccination for the prevention of cervical intraepithelial neoplasia. N. Engl. J. Med.361(3), 271–278 (2009).
   PubMed Web of Science ®Google Scholar
• Tsui IF, Poh CF, Garnis C, Rosin MP, Zhang L, Lam WL. Multiple pathways in the FGF signaling network are frequently deregulated by gene amplification in oral dysplasias. Int. J. Cancer125(9), 2219–2228 (2009).
   PubMed Web of Science ®Google Scholar
• Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy J. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood106(1), 296–303 (2005).
   PubMed Web of Science ®Google Scholar
• Rasmussen T, Kuehl M, Lodahl M, Johnsen HE, Dahl IM. Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors. Blood105(1), 317–323 (2005).
   PubMed Web of Science ®Google Scholar
• Horree N, Heintz AP, Sie-Go DM, van Diest PJ. p16 is consistently expressed in endometrial tubal metaplasia. Cell. Oncol.29(1), 37–45 (2007).
   PubMed Web of Science ®Google Scholar
• Shukla S, Gupta S. Apigenin-induced cell cycle arrest is mediated by modulation of MAPK, PI3K-Akt, and loss of cyclin D1 associated retinoblastoma dephosphorylation in human prostate cancer cells. Cell Cycle6(9), 1102–1114 (2007).
   PubMed Web of Science ®Google Scholar
• Shukla S, Gupta S. Molecular targets for apigenin-induced cell cycle arrest and apoptosis in prostate cancer cell xenograft. Mol. Cancer Ther.5(4), 843–852 (2006).
   PubMed Web of Science ®Google Scholar
• Yedjou CG, Tchounwou PB. Modulation of p53, c-fos, RARE, cyclin A, and cyclin D1 expression in human leukemia (HL-60) cells exposed to arsenic trioxide. Mol. Cell. Biochem.331(1–2), 207–214 (2009).
   PubMed Web of Science ®Google Scholar
• Leisenfelder SA, Moffat JF. Varicella-zoster virus infection of human foreskin fibroblast cells results in atypical cyclin expression and cyclin-dependent kinase activity. J. Virol.80(11), 5577–5587 (2006).
   PubMed Web of Science ®Google Scholar